Background: Patients with neuropathic pain (NeP) often receive combination therapy with multiple agents in the hopes of improving both pain and any comorbidities that may be present. While pregabalin is often recommended as a first-line treatment of NeP, few studies have examined the effects of concomitant medications on the efficacy of pregabalin.
Treatment Groups
Treatments arms included placebo, 150 mg/d fixeddose pregabalin, 300 mg/d fixed-dose pregabalin, 600 mg/d fixed-dose pregabalin, and 150 -600 mg/d flexible dose pregabalin in the PHN trials, while treatment arms included placebo and 150 -600 mg/d flexible dose pregabalin in the SCI-NeP trials. Within each treatment arm, patients were classified into 2 groups based on their use of concomitant NeP medications. Patients receiving opioids, antiepileptic drugs, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, or tramadol were included in the + concomitant NeP medications groups, whereas all other patients were included in the -concomitant NeP medications group.
Efficacy Analyses
Each day, patients rated the severity of their pain and pain-related sleep interference (PRSI) over the previous 24 hours on a scale from 0 to 10, with higher scores indicating greater severity. Changes in pain and PRSI scores were analyzed through 4, 8, and 12 weeks for the PHN cohort and through 12 weeks for the SCI cohort. First, changes in pain and PRSI scores were compared between placebo and each pregabalin treatment arm in the -concomitant NeP medications group. Then changes in pain and PRSI scores were compared between placebo and each pregabalin treatment arm in the + concomitant NeP medications group.
Finally, changes in pain and PRSI scores were compared between the -concomitant NeP medications group and the + concomitant medications group within each treatment arm, including placebo.
All efficacy analyses of pain and PRSI utilized a mixed-model repeated measures (MMRM) model with N europathic pain (NeP) is a specific type of pain resulting from a lesion or disease of the somatosensory nervous system (1, 2) . A variety of treatment options exist for the management of NeP, including antiepileptic drugs, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, opioids, and tramadol (2) (3) (4) . Despite the variety of agents available, NeP is difficult to manage. This is due in part to the severe and chronic nature of NeP and to the fact that patients with NeP often present with one or more comorbidities. For example, patients with NeP often experience disturbed sleep, anxiety, depression, and report low overall health-related quality of life (5-9). As a result, patients often receive combination therapy with multiple agents in the hopes of improving both pain and any comorbidities that may be present (10) .
Pregabalin is recommended as a first-line treatment for certain types of NeP (4, (11) (12) (13) . It is approved in the United States for the treatment of painful diabetic peripheral neuropathy (pDPN), postherpetic neuralgia (PHN), neuropathic pain due to spinal cord injury (SCI-NeP), fibromyalgia, and as adjunct therapy for partial onset seizures (14) . The analgesic, anxiolytic, and anticonvulsant properties of pregabalin are thought to be attributed to its binding to the α2δ subunit of voltage gated neuronal calcium channels and the resulting modulation of excitatory neurotransmitter release (15, 16) . The potential for pregabalin to interact with other drugs is low due to its lack of plasma protein binding, bypassing hepatic metabolism, and being excreted unchanged in the urine (17) . While this may make pregabalin a candidate agent for use in concert with other agents, few studies have been conducted of pregabalin-based combination therapy (18) . Specifically, it is unknown whether the concomitant use of other NeP agents augments or potentially diminishes the effects of pregabalin. The purpose of the current study therefore was to examine the effect of concomitant NeP medications on therapeutic response to pregabalin in patients with NeP.
Methods

Study Design
Data were derived from 9 randomized placebocontrolled trials of pregabalin for the treatment of PHN or SCI-NeP. Patients with pDPN were not included in the current analysis because clinical trials of pregabalin for the treatment of pDPN, unlike trials for PHN change from baseline in pain and PRSI as dependent variables (separate models for each); treatment, study, patients, week, and group as covariates; and interaction terms such as treatment by group and treatment by group by week. MMRM is a likelihood-based analysis that, in contrast to last-observation or baseline-observation carried forward approaches, uses all observed values from individual patients to compensate for missing values without explicitly imputing any data. The advantage of this approach is that all data are used to fit the model assumed for the response and, under a missing at random assumption, the true treatment effect is likely not to be either under-or over-estimated.
To support these primary efficacy analyses, additional sensitivity analyses were done that took into account the duration of concomitant NeP medication use. For these sensitivity analyses patients were only included in the + concomitant NeP medication group if they received concurrent NeP medication for ≥ 7 days. Patients who did not receive concurrent NeP medications or who received them for < 7 days were included in the -concomitant NeP medications group. Treatment groups were then compared as described for the primary analyses.
Safety
The combined PHN and SCI-NeP data set was analyzed for the incidence of adverse events (AEs). Weighted incidence rates were calculated for each event and those occurring in ≥ 5% of patients, in either the placebo or pregabalin (all doses combined) treatment arms, were reported for the -and + concomitant NeP medications groups. A Cochran-Mantel-Haenszel test was then used to analyze the risk difference (95% CI) between pregabalin and placebo treatment arms in the -and + concomitant NeP medications groups. Risk difference is calculated by subtracting the absolute risk with placebo from the absolute risk with pregabalin to determine the level of risk that can be attributed to treatment.
Results
Efficacy in PHN Studies
Overall, 1,401 patients were included in the PHN analysis and the percentage of patients who received concomitant NeP medications ranged from 15% -40% across all treatment arms. Patient demographics were similar between the -and + concomitant NeP medications groups in each treatment arm ( Table 2) .
The analgesic effects of pregabalin were first examined in patients who did not receive concomitant NeP medications. As expected, all doses of pregabalin significantly improved mean pain scores compared with placebo through 4, 8, and 12 weeks of treatment (Fig. 1A-C) . Similar results were evident when the analgesic effects of pregabalin were examined in patients who received concomitant NeP medications ( Fig. 1D-F (Fig. 1F) . Notably, no significant differences were noted in the extent of pain when comparing patients in the -and + concomitant NeP medications groups. This was true for all treatment (Table 3) .
Changes in PRSI scores were also examined in patients in the -and + concomitant NeP medications groups. Again, all doses of pregabalin significantly im- Fig. 2A-C) . Similar results were evident in the + concomitant NeP medications groups through 4 and 8 weeks (Fig. 2D-E) . However, only the pregabalin 300 mg/d and 600 mg/d doses significantly improved PRSI scores compared with placebo through 12 weeks (Fig. 2F) . The 150 mg/d dose trended toward improvement but did not reach the level of significance due to the large standard deviation associated with the data. The extent of pregabalin-mediated improvements in PRSI scores were not significantly different between the -and + concomitant NeP medications groups ( Table 4) .
Results of the pain and PRSI sensitivity analyses, taking into account the duration of concomitant NeP medication treatment, were similar to those of the primary analyses (data not shown). Slight differences were observed in the magnitude of treatment effects between groups due to a few patients being re-classified (from the + concomitant NeP medications group to the -concomitant NeP medications group) as a result of their having received concomitant treatment for < 7 days (see Methods for details). The number of patients changing classification from the + concomitant NeP medications group to the -concomitant NeP medications group was 30 for placebo and 24, 32, 5, and 10 for 150 mg/d-, 300 mg/d-, 600 mg/d-, and flexible pregabalin, respectively. Despite these minor differences, the overall direction and statistical significance of the comparisons were the same as the primary analyses with the following exception. In the PRSI sensitivity analyses, comparisons between the -and + concomitant NeP medications groups were no longer significant among patients receiving placebo through 4 weeks (P = 0.0871).
Efficacy in SCI-NeP Studies
Overall, 347 patients were included in the SCI-NeP analysis and the percentage of patients who received concomitant NeP medications was 43% in the placebo treatment arm and 40% in the pregabalin arm. Patient demographics were similar between the -and + concomitant NeP medications groups in each treatment arm (Table 5) .
Pregabalin significantly reduced pain scores compared with placebo through 12 weeks in both the -concomitant NeP medications (Fig. 3A) and + concomitant NeP medications (Fig. 3B) NeP patients in the + concomitant NeP medications group compared to the -concomitant NeP medications group (P = 0.03) ( Table 6 ).
Pregabalin also significantly reduced PRSI scores compared with placebo through 12 weeks in both the -concomitant NeP medications (Fig. 4A ) and + concomitant NeP medications (Fig. 4B ) groups and the extent of pregabalin-mediated relief was unaffected by the use of concomitant NeP medications ( Table 6) .
Results of the sensitivity analyses, taking into account the duration of concomitant NeP medication treatment, were similar to those of the primary analyses. Only slight differences were observed in the magnitude of treatment effects between groups, but the overall direction and statistical significance of these effects were unchanged for both the pain and PRSI analyses (data not shown). The number of patients changing classification from the + concomitant NeP medications group to the -concomitant NeP medications group was 15 for placebo and 7 for flexible pregabalin, respectively.
Safety in the Combined PHN and SCI-NeP Studies
Nine types of treatment-emergent AEs (TEAEs) were reported with weighted incidence rate of ≥ 5% in either the placebo or pregabalin (all doses combined) treatment arms in the -concomitant NeP medications group (Table 7) . Of these, 8 types (constipation, dizziness, dry mouth, fatigue, peripheral edema, somnolence, vision blurred, and weight increased) had a risk difference for pregabalin compared with placebo for which the lower limit of the 95% CI was > 0%. The AEs with the highest risk difference were dizziness (17.7%) and somnolence (15.5%).
The profile of TEAEs was similar in the + concomitant NeP medications group (Table 7) . Four types of AEs (dizziness, dry mouth, peripheral edema, and somnolence), with weighted incidence rate of ≥ 5% in either the place- conmeds = concomitant medications (includes opioids, tramadol, antiepileptic drugs, tricyclic antidepressants, and serotonin-norepinephrine reuptake inhibitors; NeP = neuropathic pain; PRSI = pain-related sleep interference; SCI-spinal cord injury; SD = standard deviation.
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discussion
The severity of pain and the presence of other comorbidities commonly results in a situation where patients with NeP receive multiple treatments simultaneously. However, some difficulties are associated with this approach. It may be difficult, for example, to assess the efficacy of a particular agent because the use of concomitant NeP treatments may mask the effects of the treatment of interest. Additionally, the potential for drug-drug interactions exists that may diminish the efficacy of one or more of the agents or result in serious adverse safety and tolerability issues.
Our study examined the efficacy of pregabalin in the context of the use of concomitant NeP mediations. Therapeutic response to pregabalin was evident compared with placebo in patients who were receiving concomitant NeP medications. This shows that there was no "floor effect" present, whereby the use of other medications could potentially mask the effects of pregabalin. Not only was a therapeutic response to pregabalin evident in patients receiving concomitant NeP medications, but the magnitude of this response for both pain and PRSI was generally unaffected by the use of concomitant NeP medications. Pain scores were slightly less improved among pregabalin treated SCI-NeP patients in the + concomitant NeP medications group compared to the -concomitant NeP medications group, though this difference was small and not evident in analyses of PRSI scores in these patients. Further no effects of concomitant NeP medications were observed in the analyses of pain and PRSI scores in patients with PHN. These analyses were based on a + concomitant NeP medications group that included all patients who had taken at least one dose of concomitant NeP medication regardless of duration. Sensitivity analyses, however, taking into account duration of concomitant NeP treatment, supported the primary analyses and further demonstrated that the use of concomitant NeP medications has little effect on therapeutic response to pregabalin. Our study also examined the safety of pregabalin in the context of the use of concomitant NeP medications. For most common AEs, the risk difference (pregabalin versus placebo) was not increased among patients who received concomitant NeP medications compared with the risk difference among patients who did not receive concomitant NeP medications and was notably lower in some cases (e.g., dizziness). This may be, in part, because patients in the placebo + concomitant NeP medications group received medications with an intrinsic risk for AEs as opposed to patients in the placebo -concomitant NeP medications group. For example, the percentage of patients experiencing dizziness and somnolence was increased by 5% -6% in the placebo + concomitant NeP medications group compared with the placebo -NeP concomitant medications group (Table 7) . Overall, our data suggest that the use of concomitant NeP medications does not increase the risk of AEs commonly associated with pregabalin. An exception to this may be the risk of peripheral edema, which was somewhat higher in patients receiving concomitant NeP medications (7.2%) compared with those who did not receive concomitant NeP medications (5.3%).
Our findings have several practical implications. First, the data demonstrate that pregabalin may have a benefit in some patients who exhibit at least moderate levels of pain despite currently receiving other treatment for NeP. In both the PHN and SCI-NeP cohorts, patients were required to have a pain score of > 4 (on a scale from 0 to 10) to be eligible for inclusion in their respective clinical trial. Our findings also suggest that physicians may keep patients on their current NeP medications, if they so desire, when introducing pregabalin to the treatment regimen, since the response to pregabalin is not diminished by concomitant NeP medications. Since there was little difference in the magnitude of therapeutic response to pregabalin in the absence and presence of concomitant NeP medications, our findings add to the current uncertainty of the value of combination therapy in the treatment of NeP (10) . For example, a trial comparing high-dose pregabalin (600 mg/d) and high-dose duloxetine (120 mg/d) to a combination of pregabalin 300 mg/d + duloxetine 60 mg/d in patients with pDPN demonstrated that this low-dose combination therapy, though well tolerated, was no more effective than either monotherapy (28) .
The original trials of pregabalin were not powered to examine the effects of concomitant NeP medications. Indeed, our analysis was limited in that there were not enough PHN patients receiving concomitant NeP medications in the flexible-dose pregabalin arm to a a Only events with weighted incidence rate of ≥ 5% of patients, in either the placebo or pregabalin (all doses combined) treatment arm, are shown. conmeds = concomitant medication. Risk differences with a lower 95% CI > 0% are in bold.
www.painphysicianjournal.com analyze their effects through 8 and 12 weeks. Additionally, though the magnitude of therapeutic response of pregabalin was unaffected by the use of concomitant NeP medications, the current study did not address the possibility that these medications affect the timing of response to pregabalin. PHN patients were analyzed through 4, 8, and 12 weeks and SCI-NeP patients were analyzed through 12 weeks. The onset of response to pregabalin, however, can occur within 2 days of initiating treatment (28) (29) (30) (31) (32) . One study in SCI-NeP patients demonstrated that concomitant NeP medications did not affect timing of response to pregabalin over the first 13 days of treatment (29) . Our findings were consistent in 2 different types of NeP: PHN, which is a classical peripheral NeP, and SCINeP, which is classified as central NeP. This is encouraging when attempting to extrapolate our findings to other NeP conditions such as pDPN. However, factors inherent to other NeP patient populations such as indication-specific comorbidities and other variables may confound such extrapolation, and care should be taken when attempting to do so. Despite these limitations the data presented here demonstrate that the therapeutic response to pregabalin for the treatment of NeP is largely unaffected by the concurrent use of other NeP medications.
